UNSPSC 51281674: Streptomycin hydrochloride

This classification denotes an aminoglycoside antibiotic with the molecular structure C21H39N7O12.3CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 8P331B9592 chemically known as d-streptamine, o-2-deoxy-2-(methylamino)-.alpha.-l-glucopyranosyl-(1->2)-o-5-deoxy-3-c-formyl-.alpha.-l-lyxofuranosyl-(1->4)-n,n'-bis(aminoiminomethyl)-, trihydrochloride, but more commonly known as streptomycin hydrochloride, which bears US NIH Compound Identifier 197844.

UNSPSC 51281674 Streptomycin hydrochloride is a Commodity code that nominally names a single pharmaceutical ingredient, but recent state and local solicitations tagged under this code show little alignment with streptomycin procurement itself. Instead, the recent opportunities reflect a broader pattern of state and local health agencies, counties, and cities buying pharmaceutical products, medical supplies, and pharmacy-benefit services — including naloxone, first-aid supplies, generic pharmaceuticals, and direct-to-manufacturer prescription programs. The issuing bodies span county health departments (Seminole County, Florida), municipal fire rescue divisions (City of Tampa), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration). The scope reflects episodic procurement of specific pharmaceutical inventory and strategic sourcing of pharmacy benefit programs rather than routine commodity purchasing.

Recent activity concentrates in Florida, Texas, and the Upper Midwest (Minnesota and Oregon). Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries and a two-year contract term with one-year renewal option. The City of Tampa issued IFB 26P00145 in March 2026 for medical and first aid supplies (169 line items) for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000, a one-year award period with two optional one-year renewals, and a 5 percent bid discount sheltered for certified Small Local Business Enterprises. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 seeking generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, a two-year contract term, and evaluation weighted 75 percent on price competitiveness. The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs, reflecting exploratory procurement strategy rather than immediate buying intent. The code shows mixed recent activity with no apparent concentration among repeat issuers.